Autonomix Medical Inc Dossier
Qualitative Analysis
Business overview
Autonomix Medical, Inc. (NASDAQ: AMIX) is a development-stage medical device company focused on advancing innovative technologies for sensing and treating disorders relating to the peripheral nervous system. The company's first-in-class platform technology features a catheter-based microchip-enabled sensing array designed to detect and differentiate low-amplitude neural signals with high sensitivity. This technology is intended to enable a precision-guided "sense, treat, and verify" workflow, utilizing proprietary radiofrequency (RF) ablation to target and destroy specific nerves. Autonomix is initially developing this platform for the treatment of severe, debilitating pain associated with pancreatic cancer. Beyond oncology pain, the company envisions broad therapeutic applications for its platform across resistant hypertension, cardiology, pulmonology, and gastroenterology. Currently, the company's technology is investigational and has not yet been cleared for marketing in the United States.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the proprietary Sensing and RF Ablation System through FDA regulatory channels, utilizing a De Novo pathway supported by preclinical GLP studies and planned U.S. IDE clinical trials.
Expected impact: Securing FDA clearance to commercialize the system in the United States for pancreatic cancer pain management.
Initiating a follow-on Proof-of-Concept (PoC 2) phase to evaluate the Sensing and RF Ablation System in additional visceral cancers (such as liver, gallbladder, and bile duct) and earlier-stage pancreatic cancer.
Expected impact: Potentially doubles the addressable market beyond pancreatic cancer pain management by targeting other cancers signaling pain through the Celiac Plexus.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants Autonomix a perpetual, non-exclusive, worldwide, and royalty-free license to the IP of the FDA-cleared Apex 6 Radiofrequency Generator, simplifying Autonomix's regulatory strategy and accelerating platform development.
Terms: Autonomix issued 250,000 shares of its common stock to RF Innovations, Inc. as consideration for the license.
Regained exclusive worldwide rights to Autonomix's technology for cardiology field use, broadening development opportunities and strategic optionality.
Terms: Terminated the prior license agreement in exchange for a warrant to purchase 1,600,000 shares of common stock at an exercise price of $0.001 per share (based on a fixed value of $8 million divided by the $5.00 IPO price).